Clinical Trials Browser

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT03944304 2026-04-03

Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.

Phase 2 Completed

40 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01303497 2026-03-13

ANGIO-TAX+

Phase 2 Completed

70 enrolled

Sarcoma

Hemangiosarcoma

NCT05799612 2026-02-13

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Phase 1 Withdrawn

Sarcoma

Hemangiosarcoma

NCT05411237 2026-01-23

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma

Phase 3 Not yet recruiting

130 enrolled

Sarcoma

AIDS-related Kaposi sarcoma, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

Clinical Trials

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

9-ING-41 in Patients With Advanced Cancers

Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.

I-SPY

ANGIO-TAX+

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma